Kazia Therapeutics Preço/Vendas
Qual é o Preço/Vendas de Kazia Therapeutics?
O Preço/Vendas de Kazia Therapeutics Limited é 1.93
Qual é a definição de Preço/Vendas?
A razão entre preço e vendas é o preço das ações de uma empresa em comparação com as suas receitas.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Preço/Vendas de empresas na Setor Health Care em ASX em comparação com Kazia Therapeutics
O que Kazia Therapeutics faz?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Empresas com preço/vendas semelhantes a Kazia Therapeutics
- Grand T G Gold tem Preço/Vendas de 1.92
- C4X Discovery Plc tem Preço/Vendas de 1.93
- China ITS () Co tem Preço/Vendas de 1.93
- Kandi Technologies tem Preço/Vendas de 1.93
- Obsidian tem Preço/Vendas de 1.93
- Whiting Petroleum Dl ,001 tem Preço/Vendas de 1.93
- Kazia Therapeutics tem Preço/Vendas de 1.93
- The Indian Card Clothing tem Preço/Vendas de 1.93
- Qingdao Port International Co tem Preço/Vendas de 1.93
- Anheuser-Busch InBev SA/NV tem Preço/Vendas de 1.93
- Kiri Industries tem Preço/Vendas de 1.93
- EyePoint Pharmaceuticals Inc tem Preço/Vendas de 1.93
- Cerebra Integrated Technologies tem Preço/Vendas de 1.93